Advanced Biomed is a pre-revenue medical device company developing liquid biopsy tools for cancer detection and monitoring. Its core technology is a suite of microfluidic devices and biochips that isolate and analyze circulating tumor cells (CTCs) — cancer cells shed by tumors into the bloodstream — from patient blood samples. The workflow uses three devices in sequence: A+Pre pre-processes blood samples, AC-1000 separates and enriches CTCs using a physical, label-free mechanism, and A+CellScan and A+SCDrop handle downstream analysis including AI-based CTC identification and single-cell isolation for sequencing and drug sensitivity testing. Advanced Biomed also has four immunostaining kits that identify specific CTC subtypes, a lung cancer screening kit in clinical development (A+LCGuard), and a 3D cell culture incubator that grows tumor organoids to predict drug response. Target customers are hospitals and clinical laboratories. The intended business model combines instrument sales with recurring revenue from consumable microfluidic chips and reagent kits, consumed on a per-patient-per-test basis. Advanced Biomed also plans to offer OEM manufacturing of custom microfluidic components for third parties. Several products have cleared China's NMPA as Class I devices, while others are in review or clinical development. The company plans to pursue U.S. FDA and EU CE clearances, with U.S. operations planned to begin in 2025. Advanced Biomed expects to remain pre-revenue for the next two to three years while completing the regulatory process, and is currently funded through equity issuance.